Literature DB >> 12702898

Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis.

Staffan Hägg1, Staffan Rosenius, Olav Spigset.   

Abstract

Short-term treatment with granulocyte colony-stimulating factor has been successful in reducing the duration of clozapine-induced agranulocytosis. Long-term combination treatment with filgrastim and clozapine in patients with clozapine-induced agranulocytosis has only been described in two previous cases. We describe three patients with schizophrenia who developed granulocytopenia or agranulocytosis during treatment with clozapine and who did not respond to other antipsychotics. The patients received long-term combination treatment with clozapine and filgrastim. Using a combination treatment with filgrastim and clozapine, the psychotic symptoms were successfully controlled and no haematological complications were observed during the follow-up periods of 11, 30 and 48 months, respectively. Our cases suggest that long-term treatment with filgrastim might be a useful, but exceptional, treatment approach in patients who have developed clozapine-induced granulocytopenia or agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702898     DOI: 10.1097/01.yic.0000062800.74434.6c

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  11 in total

Review 1.  Continuing clozapine treatment despite neutropenia.

Authors:  David Esposito; Frédéric Rouillon; Frédéric Limosin
Journal:  Eur J Clin Pharmacol       Date:  2004-11-30       Impact factor: 2.953

Review 2.  Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports.

Authors:  Memduha Aydin; Bilge Cetin Ilhan; Saliha Calisir; Seda Yildirim; Ibrahim Eren
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

3.  Changes for clozapine monitoring in the United States.

Authors:  T Bastiampillai; A Gupta; S K W Chan; S Allison
Journal:  Mol Psychiatry       Date:  2016-05-03       Impact factor: 15.992

Review 4.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

Review 6.  Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma.

Authors:  Nazife Gamze Usta; Cana Aksoy Poyraz; Melih Aktan; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

Review 7.  Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Authors:  Michael Berk; Joanna Fitzsimons; Timothy Lambert; Christos Pantelis; Jayashri Kulkarni; David Castle; Elizabeth W Ryan; Sean Jespersen; Pat McGorry; Gregor Berger; Bill Kuluris; Tom Callaly; Seetal Dodd
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  The blood brain barrier and the role of cytokines in neuropsychiatry.

Authors:  Atmaram Yarlagadda; Elizabeth Alfson; Anita H Clayton
Journal:  Psychiatry (Edgmont)       Date:  2009-11

9.  Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia.

Authors:  Al Aditya Khan; Jake Harvey; Samrat Sengupta
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

10.  Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: A case report and discussion.

Authors:  Allison Karst; Jonathan Lister
Journal:  Ment Health Clin       Date:  2018-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.